Company Encyclopedia
View More
name
Froniter Biotechnologies
688221.SH
Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients’ health in China. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company’s products under development include small RNA drugs, such as FB7011/FB7013/FB7014 to treat IgA nephropathy, FB7022/FB7021 for dyslipidemia, and FB7012/FB7041/FB7031/FB7032 for various other diseases, including hyperuricemia and gout, tumors, and metabolic-associated fatty liver diseases; FB4001, to treat patients with osteoporosis or high risk of fracture; and FB3002, for the treatment of pain in muscles, bones, and joints. Frontier Biotechnologies Inc.
1.601 T
688221.SHMarket value -Rank by Market Cap -/-

Financial Score

08/11/2025 Update
D
BiotechnologyIndustry
Industry Ranking68/79
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-15.74%E
    • Profit Margin-118.79%E
    • Gross Margin40.09%B
  • Growth ScoreC
    • Revenue YoY5.63%C
    • Net Profit YoY40.09%B
    • Total Assets YoY-18.36%E
    • Net Assets YoY-14.59%E
  • Cash ScoreC
    • Cash Flow Margin-84.18%D
    • OCF YoY5.63%C
  • Operating ScoreE
    • Turnover0.08E
  • Debt ScoreC
    • Gearing Ratio40.06%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    The chemical pharmaceutical sector rose in early trading, with SUNFLOWER hitting the daily limit of a 20cm increase

    The chemical pharmaceutical sector rose in early trading, with SUNFLOWER hitting the daily limit of a 20cm increase, followed by gains in Froniter Biotechnologies, HUIYU PHARMACEUTICAL, JIUDIAN PHARMACEUTICAL, KELUN PHARMA, and Yuandong Biotech

    Zhitong·
    SH
    688553
    -1.42%
    SZ
    300705
    +0.24%
    SZ
    002422
    -2.91%
    Zhitong·
    SH
    688553
    -1.42%
    SZ
    300705
    +0.24%
    SZ
    002422
    -2.91%

    Froniter Biotechnologies plans to launch a restricted stock incentive plan in 2025

    Froniter Biotechnologies released a draft of the 2025 restricted stock incentive plan, proposing to grant 5 million shares of restricted stock, accounting for 1.33% of the company's total share capital. The initial grant will be 4.25 million shares, with 750,000 shares reserved, and the grant price is set at 8.56 yuan per share. The incentive plan has a maximum validity period of 36 months

    Zhitong·
    SH
    688221
    -0.07%
    Zhitong·
    SH
    688221
    -0.07%

    Innovative drug concept stocks are repeatedly active, Chimin hits the daily limit

    Innovative drug concept stocks are repeatedly active, Chimin hit the daily limit, JENKEM rose over 10%, YKYY, Nossan, Frontier Biotechnologies, Salubris, and HitGen followed suit

    Zhitong·
    SH
    688356
    -1.62%
    SH
    688658
    -0.29%
    SH
    688221
    -0.07%
    Zhitong·
    SH
    688356
    -1.62%
    SH
    688658
    -0.29%
    SH
    688221
    -0.07%

    Innovative drug concept stocks rose at the beginning of the trading session, YKYY increased by over 10%

    Innovative drug concept stocks rose at the beginning of trading, with YKYY up over 10%, Froniter Biotechnologies up over 9%, and CSBIO, Porton, and Foyou Pharma leading in gains

    Zhitong·
    SZ
    300255
    -0.80%
    SZ
    300363
    -1.36%
    SH
    601089
    -0.77%
    Zhitong·
    SZ
    300255
    -0.80%
    SZ
    300363
    -1.36%
    SH
    601089
    -0.77%

    Froniter Biotechnologies: Net loss of 97.3526 million yuan in the first half of 2025, a year-on-year narrowing

    Froniter Biotechnologies announced that in the first half of 2025, operating revenue was 58.6398 million yuan, a year-on-year increase of 14.85%. The net loss attributable to shareholders of the listed company was 97.3526 million yuan, compared to a net loss of 160 million yuan in the same period last year. The basic earnings per share were -0.26 yuan/share, compared to -0.43 yuan/share in the same period last year

    Zhitong·
    SH
    688221
    -0.07%
    Zhitong·
    SH
    688221
    -0.07%